SecBot SecBot

CSTL

CASTLE BIOSCIENCES INC
Nasdaq· Services-Medical Laboratories· Inc. DE· CIK 0001447362 Biotech & Drug Discovery
$33.30 +0.22 (+0.67%)
Oct 26 4:00 PM ET · prev $33.08
Market cap
$1.0B
Small cap
Consensus
Buy
93% Buy or better · 15 analysts
Median target
$45.00
+35% · range $35.00–57.00
Next earnings
Nov 5
in 10 days
1 year
+39.0%
from $23.96 · Oct 27
30 days
−7.3%
from $35.93
52-week range
$18.15–43.04
−23% from high · low May 13
Avg volume 20D
341.4K
shares / day
Short interest
2.00M
≈6.5% of shares · +5.3%
Days to cover
4.8
at average volume
Insider net
−$5.6M
0 buyers · 4 sellers · since Aug 14
New fund stakes
1
Q2 2026 13F · 0 exits
SecBot read BEARISH 16 reports · 90 days
Balance 3 bearish · 0 bullish · 13 neutral oldest → newest, height = score
Avg score ·High conf. 9/16 ·Next Earnings date, Nov 5, 2026
Strongest NEUTRAL CEO Derek Maetzold filed a Form 144 notice of intent to sell 28,992 shares of Castle Biosciences common…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBEARISH

    4 insiders sold $5.6M.

  • InstitutionsBULLISH

    Q2 2026: 24 added (1 new), 13 trimmed or exited. Largest new: Jefferies Financial Group $15.4M.

  • AnalystsBULLISH

    14 of 15 rate it Buy or better. Every target is above the price.

  • Short sellersSTEADY

    Short interest +5.3% to 2.00M shares. 4.8 days to cover, ≈6.5% of shares.

  • TrendDOWNTREND

    1% below its 50-day average.

Who's buying

13F· Q2 2026
1
new positions
0
exits
$15.4M
in new stakes
FundMoveSharesValue
MACKENZIE FINANCIAL CORPDOUBLED793,507$18.9M
Jefferies Financial Group Inc.NEW647,391$15.4M
RENAISSANCE TECHNOLOGIES LLCTRIM371,200$8.9M
PANAGORA ASSET MANAGEMENT INCADD301,040$7.2M
Allspring Global Investments Holdings, LLCADD292,470$7.0M
WASATCH ADVISORS LPTRIM279,349$6.7M
CITADEL ADVISORS LLCDOUBLED265,353$6.3M
Nuveen, LLCTRIM231,726$5.5M

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

15 analysts
Buy 93% rate it Buy or better
Strong Buy7Buy7Hold1Sell0Strong Sell0
12-month targets · 9 analysts

Price is below the lowest target. Median implies +35%.Targets as of Oct 26, 2026.

Recent actions
DateFirmActionRating
Aug 3, 2026BTIG
MAINTAIN
MAINTAINBuy
Jun 25, 2026Roth Capital
INITIATE
INITIATEBuy
May 13, 2026BTIG
MAINTAIN
MAINTAINBuy
May 7, 2026Baird
MAINTAIN
MAINTAINOutperform

Insider ledger

Form 4
$0
bought · 0 insiders
$5.6M
sold · 4 insiders
DateInsiderTypeValue
Oct 19, 2026
MAETZOLD DEREK J
Pres. & Chief Exec. Officer
SELL$273.8K
Oct 19, 2026
MAETZOLD DEREK J
Pres. & Chief Exec. Officer
SELL$102.0K
Oct 19, 2026
MAETZOLD DEREK J
Pres. & Chief Exec. Officer
SELL$86.7K
Oct 12, 2026
Juvenal Tobin W
Chief Commercial Officer
SELL$110.6K
Oct 5, 2026
MAETZOLD DEREK J
Pres. & Chief Exec. Officer
SELL$96.7K
Oct 5, 2026
MAETZOLD DEREK J
Pres. & Chief Exec. Officer
SELL$113.7K
Oct 5, 2026
MAETZOLD DEREK J
Pres. & Chief Exec. Officer
EXERCISE$19.5K
Oct 5, 2026
MAETZOLD DEREK J
Pres. & Chief Exec. Officer
SELL$305.2K

Earnings setup

Estimates
Nov 5
reports in 10 days

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY-$0.91-$1.56–-$0.43+7.6%$412.5M

Short side

FINRA· Sep 30, 2026
1,999,726
shares short
+5.3%
vs prior settlement
4.8
days to cover
≈6.5%
of shares outstanding
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 21, 2026 SEC
Two Castle Biosciences insiders, including the CEO, sold a combined $384K in open-market sales over a one-week window…
CLUSTER — Impact 3/10
Oct 19, 2026 Insider
MAETZOLD DEREK J sold 8,580 shares
Pres. & Chief Exec. Officer @ $31.91 ($273.8K)
Oct 19, 2026 Insider
MAETZOLD DEREK J sold 3,198 shares
Pres. & Chief Exec. Officer @ $31.91 ($102.0K)
Oct 19, 2026 Insider
MAETZOLD DEREK J sold 2,718 shares
Pres. & Chief Exec. Officer @ $31.91 ($86.7K)
Oct 5, 2026 SEC
CEO Derek Maetzold filed a Form 144 notice of intent to sell 28,992 shares of Castle Biosciences common stock, with an…
144 — Impact 4/10
Oct 5, 2026 SEC
Two C-suite insiders at Castle Biosciences sold a total of ~$136K in open-market sales over a 3-day period. The Chief…
CLUSTER — Impact 2/10
Sep 28, 2026 Other
New Study Shows That TissueCypher® Changed Management at an Expert Surgery Center in 90% of Patients With Non-Dysplastic Barrett's Esophagus
FRIENDSWOOD, Texas, Sept. 28, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a compan
Jun 30, 2026 Inst.
MACKENZIE FINANCIAL CORP — DOUBLED
793,507 shares ($18.9M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 5, 2026
Earnings date
CSTL Q3 2026 Earnings Scheduled — 2026-11-05
Recent
Sep 28, 2026
Press release
New Study Shows That TissueCypher® Changed Management at an Expert Surgery Center in 90% of Patients With Non-Dysplastic Barrett's Esophagus
FRIENDSWOOD, Texas, Sept. 28, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that…
Sep 22, 2026
Press release
Castle Biosciences to Open New Laboratory Facility in Scottsdale
New 55,000-square-foot facility expands Castle's operational footprint in Arizona to support growing test volumes and long-term growth FRIENDSWOOD…
Aug 20, 2026
Press release
Castle Biosciences to Participate in Upcoming Investor Conferences
FRIENDSWOOD, Texas, Aug. 20, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that…
Aug 17, 2026
Press release
Castle Biosciences Approved for Dual Listing on Nasdaq Texas
FRIENDSWOOD, Texas, Aug. 17, 2026 /PRNewswire/ -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that…
Jul 30, 2026
Earnings date
CSTL Q2 2026 Earnings Scheduled — 2026-07-30

SecBot reports

29 filings · 2 press releases · 0 bullish · 8 bearish · 21 neutral
All CSTL filing & press-release reports (31)